MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET

Company Participants

Zack Armen - Head, Investor Relations
Jennifer Buell - President and Chief Executive Officer
Marc Van Dijk - Chief Scientific Officer
Christine Klaskin - Principal Financial and Accounting Officer

Conference Call Participants

Emily Bodnar - H.C. Wainwright
Jack Allen - Baird
Mayank Mamtani - B. Reilly Securities

Operator

Good day everyone, and welcome to the MiNK Therapeutics' Fourth Quarter 2023 Financial Results. Today’s call is being recorded. All lines have been placed on mute to prevent any background noise and after the speakers’ remarks, there will be a question and answer session. [Operator Instructions]

I would now like to turn the conference over to Zack Armen, Head of Investor Relations. Please go ahead.

Zack Armen

Thank you, Lisa, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay.

I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data release and partnership opportunities among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.

Joining me today are Doctor Jennifer Buell, President and Chief Executive Officer; Christine Klaskin, Principal Financial and Accounting Officer and Doctor Marc Van Dijk, Chief Scientific Officer. Doctor Joy Zhou, Head of CMC is also here for any questions.

Now, I'd like to turn the call over to Doctor Buell to highlight our progress in 2023 and to speak to our outlook for 2024.

Jennifer Buell

Thank you very much, Zack. It's a pleasure to have you all with us this morning to hear about our accomplishments throughout the course of last year and what we plan to do in 2024. Throughout 2023 and into the beginning of this year already, we've achieved some significant milestones that I'm going to go through today. And these are all related to advancing our allogenic iNKT or Invariant Natural Killer T cell programs.

Notably, we initiated phase – a phase 2 trial in gastroesophageal cancer, a development I’ll delve into very shortly. This pivotal program built upon crucial data presented at four major medical conferences throughout the course of 2023, along with the publication of our findings in esteemed journals, such as Nature Communications and Oncogene.